Danger Zone: athenahealth (ATHN)

Check out this week’s Danger Zone interview with Chuck Jaffe of Money Life and MarketWatch.com.

Athenahealth (stylized as athenahealth) is a cloud-based provider of software and services to the health care industry. Specifically, athenahealth is an electronic health record management company with cloud-based practice management and patient communication services. Although the stock has fallen 39% from its highs in February 2014, we think it has much further to fall.

It’s hard to short cloud stocks in this environment, and we’ve been burned before. However, there are a few tailwinds that athenahealth has been benefitting from that have disappeared, making this stock’s short prospects even better. Increased competition in the healthcare cloud services space has eroded athenahealth’s profitability and the company’s future looks much less profitable than it did several years ago.

What is athenahealth?

Athenahealth operates in a subset of the Technology sector that serves the health care industry through the provision of electronic health records, or EHRs. This market is further broken down into companies that serve primarily inpatient customers (think large hospitals and institutions) and ambulatory customers (physician practices and clinics). Athenahealth’s customers are primarily in the ambulatory market.

Athenahealth has four main segments that collect payments from physicians’ customers, manage EHRs, communicate with patients and manage referral cycles. All four of these together are referred to as “Business Services,” and comprise a majority of the company’s revenue. Athenahealth’s revenue is generated by charging a service fee based on the percentage of a physician’s bills collected.

Revenue Growth is Becoming Too Expensive

Athenahealth, like many cloud companies, has seen some impressive revenue growth over its lifetime. However, while athenahealth was once growing revenues by 39% annually, growth in 2014 slowed to 27% annually.

Not only is athenahealth’s revenue growth slowing, but it’s also becoming more expensive. Since 2011, athenahealth’s after-tax profit (NOPAT) has declined each year by 43% compounded annually. The company earned a NOPAT of just $4 million in 2014, well below the company’s IPO NOPAT of $7 million in 2007. As a result, athenahealth’s return on invested capital (ROIC) has fallen from 14% in 2011 to 0.5% in 2014.

What’s been happening to athenahealth’s profits? Two words: margin compression.

Athenahealth’s NOPAT margins have fallen each year from 6% in 2011 to 0.5% in 2014. Revenue growth that once came cheap and easy is now expensive. The company has a cumulative -$652 million in free cash flow since going public in 2007.

A classic lesson from Finance 101 is that a highly profitable business attracts new entrants. This is undoubtedly what’s been happening at athenahealth, as a multitude of EHR companies have entered the market, which has placed pricing pressure on athenahealth’s offerings.

As shown in Figure 1 below, competition has destroyed athenahealth’s economic profit:
Athenahealth’s growth had benefitted from two tailwinds:

The first is government subsidies. EHR providers have been riding a wave thanks mostly to Uncle Sam as acts such as the Health Information Technology for Economic and Clinical Health Act (HITECH) resulted in over $30 billion of government funding to upgrade EHRs. Athenahealth especially has been cashing in on the adoption of EHRs. However, this short-term tailwind is set to disappear, as the bill’s funding is running out. A few years ago when HITECH was enacted, doctors were paid $44,000 to implement and use an EHR. Late last year this dropped to $24,000, and in a few months the incentive will disappear altogether.

The second tailwind is positive publicity in the eyes of the health care industry. In 2005, EHR giant Cerner (CERN) and other companies paid for a report by the RAND Corporation that predicted substantial efficiencies resulting from the adoption of electronic health records. This report helped drive growth in the EHR business and the billions of dollars from the HITEC act. Cerner’s revenue tripled from 2005 to 2013, while athenahealth’s increased six fold from 2007 to 2013.

However, a 2013 reassessment of the 2005 report by the RAND Corporation said that the conversion to EHRs had failed to produce savings and had mixed results in terms of efficiency and patient care. Accordingly, the revenue growth of many EHR companies — Cerner, athenahealth, and Allscripts (MDRX), for example — is slowing or has stopped altogether. In athenahealth’s case, revenue growth has slowed across the past five quarters: from 48% in 4Q13 to 24% in 4Q14. The company is projecting around 20% revenue growth for all of 2015, far below its 30% target from 2012.

Weak Competitor

While athenahealth is focused on the smaller ambulatory market, companies like Cerner and Epic Systems (a private company) have the larger inpatient customers. Allscripts is perhaps the most similar competitor to ATHN given that they both have large market shares in the ambulatory EHR space and not within large hospitals.

Figure 2 below compares athenahealth with Allscripts, and then the two with Cerner, which focuses on large inpatient clients.
Figure 2: No True Competitor

<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>NOPAT Margin</th>
<th>ROIC</th>
<th>PEBV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerner</td>
<td>CERN</td>
<td>16%</td>
<td>21%</td>
<td>3.7</td>
</tr>
<tr>
<td>Allscripts</td>
<td>MDRX</td>
<td>-2%</td>
<td>-1%</td>
<td>-3</td>
</tr>
<tr>
<td>athenahealth</td>
<td>ATHN</td>
<td>-7%</td>
<td>-8%</td>
<td>-14.2</td>
</tr>
</tbody>
</table>

Sources: New Constructs, LLC and company filings.

Note how low margins are in the ambulatory EHR space. Allscripts is seeing very similar margin compression to athenahealth with NOPAT margins having declined every year since 2010.

Now note Cerner’s margins. This is the market athenahealth must break into if it is to achieve anywhere close to what its stock’s valuation implies. Athenahealth will have a lot harder time attacking larger customers, which are already hooked by Cerner and Epic’s complex systems that will be costly to change over.

Allscripts has more than 180,000 physician users and has solutions in 2,700 hospitals and 13,000 extended care organizations, while athenahealth has just over 62,000 users. As a comparison, nearly 190 million American medical records, more than half of the United States population, are already stored using Epic Software Solutions. Roughly 275,000 doctors are already using the software as well, which illustrates the uphill battle that athenahealth has to break into this market.

These Adjustments Impact Our Thesis on athenahealth

We made several adjustments to athenahealth’s reported financials in 2014 to ensure that our picture of the company’s fundamentals is as clear as possible. Our NOPAT calculation of $4 million is actually higher than athenahealth’s reported loss of -$3 million due to the removal of $5 million in non-operating expenses and $5 million in implied interest expense from operating leases. In other words, even though our data shows that the company made money last year, we’re still bearish.

In addition, athenahealth has $209 million in reported debt, but $110 million in off-balance sheet debt from operating leases brings athenahealth’s total debt to $319 million, or over 7% of the company’s market value.

Valuation Ignores Current State of the Business

Despite athenahealth’s evaporating profits, competitive struggles and fading tailwinds, the stock’s valuation has continued to climb higher.

To justify its current price of $127/share, athenahealth must grow NOPAT by 60% compounded annually for the next 12 years. Under this scenario, we assume that athenahealth will achieve 10% pretax margins going forward, equal to its all-time high margins achieved in 2010.

If athenahealth can, instead, achieve pre-tax margins of 5% (still five times higher than its current margins) and grow NOPAT by 23% compounded annually for the next 20 years, the stock is worth just $15/share, an 88% downside from current levels. Remember that athenahealth is on track to achieve around 23% revenue growth this year after six consecutive quarters of revenue decline. 23% extended profit growth looks optimistic when considering the competition in the space and the downward trend in athenahealth’s revenue growth and profits.

Little Stupid Money Risk

Athenahealth currently has no dividend and no buyback. It’s possible that a larger competitor will buy out the company, but that looks unlikely at these inflated valuations. An acquirer will likely wait until some of the investor optimism around the stock subsides, or until athenahealth acquires even more clients at a loss to make what is perhaps the company’s largest asset — its client list — even more valuable.

These Catalysts Make ATHN Far Too Dangerous

We can identify a few forces that might cause athenahealth’s bubble to pop. As we mentioned earlier, revenue growth slowed to 24% in the most recent quarter. If this continues to lag behind athenahealth’s promised rate of 30%, investors will jump ship. A catalyst for this event is the existing HITEC subsidies for EHR adoption running dry. Finally, athenahealth insiders could dump even more stock (see below).
Follow the Insiders’ Lead
In the past six months, insiders have bought no shares and sold 161,000 shares, a net decrease of 26% of insiders’ total holdings. Included in this group is the company’s CEO Jonathan Bush, who has continuously dumped $4 million in stock since the beginning of 2014.

High Short Interest
Short interest stands at 9.7 million shares, or almost 26% of float.

Dangerous Funds That Hold ATHN
The following ETFs and mutual funds allocate significantly to ATHN and earn our Dangerous or Very Dangerous ratings. Note that we recently featured ARKK in our list of the five riskiest ETFs.

1. Ark Innovation ETF (ARKK) — 5.9% allocation to ATHN and Very Dangerous rating
2. Ark Web x.0 ETF (ARKW) — 5.3% allocation to ATHN and Dangerous rating
3. Transamerica Growth Opportunities Fund (ITSLX, ITSAX, ITCBX, TGPIX) — 3.5% allocation to ATHN and Very Dangerous rating

Allen Jackson contributed to this report.

Disclosure: André Rouillard and Allen Jackson receive no compensation to write about any specific stock, sector, or theme.
**New Constructs® – Profile**

**How New Constructs Creates Value for Clients**

1. **Superior Recommendations** – Our [stock picks](#) consistently outperform. See our track record in our [stock-picking accolades](#) and [Proof Is In Performance](#) reports.

2. **More Accurate Research** – Our [patented Research Platform](#) for reversing accounting distortions and discounted cash flow analysis leverages better data to deliver smarter research.

3. **Time Savings** – We check the fine print in thousands of corporate filings so you don't have to. As reported by *Barron’s*, our expertise in analyzing SEC filings delivers [Hidden Gems and Red Flags](#) that drive long-term stock-picking success.

4. **Transparency** – We are proud to share the results of our analysis of over 50,000 10Ks. See the [Corporate Disclosure Transgressions](#) report we provided the SEC. Our reports detail all data and assumptions. Company Models enable users to change them.

5. **Objectivity** – New Constructs is an independent research firm, not tied to Wall Street or investment banking services. Our models are driven by comprehensive high-quality data not stories. See our [presentation to the Senate Banking Committee](#), the SEC and many others in DC.

**Our Philosophy About Research**

Accounting data is not designed for equity investors, but for debt investors. [Accounting data must be translated into economic earnings](#) to understand the profitability and valuation relevant to equity investors. Respected investors (e.g. Adam Smith, Warren Buffett and Ben Graham) have repeatedly emphasized that accounting results should not be used to value stocks. [Economic earnings](#) are what matter because they are:

1. Based on the complete set of financial information available.
2. Standard for all companies.
3. A more accurate representation of the true underlying cash flows of the business.

**Additional Information**

Incorporated in July 2002, [New Constructs](#) is an independent publisher of investment research that provides clients with consulting and research services. We specialize in quality-of-earnings, forensic accounting and discounted cash flow valuation analyses for all U.S. public companies. We translate accounting data from 10Ks into economic financial statements, i.e. [NOPAT](#), [Invested Capital](#), and [WACC](#), to create [economic earnings models](#), which are necessary to understand the true profitability and valuation of companies. Visit the [Free Archive](#) to download samples of our research. New Constructs is a [BBB accredited](#) business and a member of the [Investorside Research Association](#).
DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, “New Constructs”) is an independent organization with no management ties to the companies it covers. None of the members of New Constructs’ management team or the management team of any New Constructs’ affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs’ Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

New Constructs is affiliated with Novo Capital Management, LLC, the general partner of a hedge fund. At any particular time, New Constructs’ research recommendations may not coincide with the hedge fund’s holdings. However, in no event will the hedge fund receive any research information or recommendations in advance of the information that New Constructs provides to its other clients.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstances, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

New Constructs’ reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs.

Copyright New Constructs, LLC 2003 through the present date. All rights reserved.